BACKGROUND: The angiotensin-converting enzyme (ACE) deletion allele, ACE D, is associated with increased ACE activity and adverse outcomes in cardiovascular disease. Although activation of the renin-angiotensin-aldosterone system (RAAS) now appears to play a role in the pathophysiology of atrial fibrillation (AF), it remains to be determined if ACE genotype impacts response to conventional AAD therapy in patients with AF. OBJECTIVES: The purpose of this study was to investigate whether response to antiarrhythmic drug (AAD) therapy in patients with AF is modulated by the ACE I/D polymorphism. METHODS: We studied 213 patients (147 men, 66 women; ages 52 +/- 15 years) prospectively enrolled in the Vanderbilt AF Registry. AAD therapy outcome was defined prospectively as response if there was a >or=75% reduction in symptomatic AF burden or nonresponse if AF burden was unchanged, necessitating a change in drugs or therapy. RESULTS: Lone AF (age <65 years, no identifiable cause) was present in 72 (34%) patients, whereas hypertension was the most common underlying disease in the remaining 141 (41%). AF was paroxysmal in 170 (80%) and persistent in 43 (20%). The frequencies of the DD, ID, and II genotypes were in Hardy-Weinberg equilibrium. Lone AF and DD/ID genotypes were highly significant predictors of failure of drug therapy (P <.005). In patients with lone AF, failure of drug response was 5%, 41%, and 47% in patients with II, ID, and DD genotypes, respectively, (P <.005, II vs. ID/DD). CONCLUSIONS: These results provide further evidence for a role of RAAS activation in the pathophysiology of AF and point to a potential role for stratification of therapeutic approaches by ACE genotype.
BACKGROUND: The angiotensin-converting enzyme (ACE) deletion allele, ACE D, is associated with increased ACE activity and adverse outcomes in cardiovascular disease. Although activation of the renin-angiotensin-aldosterone system (RAAS) now appears to play a role in the pathophysiology of atrial fibrillation (AF), it remains to be determined if ACE genotype impacts response to conventional AAD therapy in patients with AF. OBJECTIVES: The purpose of this study was to investigate whether response to antiarrhythmic drug (AAD) therapy in patients with AF is modulated by the ACE I/D polymorphism. METHODS: We studied 213 patients (147 men, 66 women; ages 52 +/- 15 years) prospectively enrolled in the Vanderbilt AF Registry. AAD therapy outcome was defined prospectively as response if there was a >or=75% reduction in symptomatic AF burden or nonresponse if AF burden was unchanged, necessitating a change in drugs or therapy. RESULTS: Lone AF (age <65 years, no identifiable cause) was present in 72 (34%) patients, whereas hypertension was the most common underlying disease in the remaining 141 (41%). AF was paroxysmal in 170 (80%) and persistent in 43 (20%). The frequencies of the DD, ID, and II genotypes were in Hardy-Weinberg equilibrium. Lone AF and DD/ID genotypes were highly significant predictors of failure of drug therapy (P <.005). In patients with lone AF, failure of drug response was 5%, 41%, and 47% in patients with II, ID, and DD genotypes, respectively, (P <.005, II vs. ID/DD). CONCLUSIONS: These results provide further evidence for a role of RAAS activation in the pathophysiology of AF and point to a potential role for stratification of therapeutic approaches by ACE genotype.
Authors: A Goette; T Staack; C Röcken; M Arndt; J C Geller; C Huth; S Ansorge; H U Klein; U Lendeckel Journal: J Am Coll Cardiol Date: 2000-05 Impact factor: 24.094
Authors: A Goette; M Arndt; C Röcken; A Spiess; T Staack; J C Geller; C Huth; S Ansorge; H U Klein; U Lendeckel Journal: Circulation Date: 2000-06-13 Impact factor: 29.690
Authors: Patrick T Ellinor; Jordan T Shin; Rachel K Moore; Danita M Yoerger; Calum A MacRae Journal: Circulation Date: 2003-06-02 Impact factor: 29.690
Authors: Gerald S Bloomfield; Tecla M Temu; Constantine O Akwanalo; Peng-Sheng Chen; Wilfred Emonyi; Susan R Heckbert; Myra M Koech; Imran Manji; Changyu Shen; Matteo Vatta; Eric J Velazquez; Jennifer Wessel; Sylvester Kimaiyo; Thomas S Inui Journal: Am Heart J Date: 2015-06-14 Impact factor: 4.749
Authors: M Benjamin Shoemaker; Sanaz Gidfar; Daniel C Pipilas; Robyn A Tamboli; Eleonora Savio Galimberti; D Brandon Williams; Ronald H Clements; Dawood Darbar Journal: Obes Surg Date: 2014-04 Impact factor: 4.129
Authors: Stefan Kääb; Dawood Darbar; Charlotte van Noord; Josée Dupuis; Arne Pfeufer; Christopher Newton-Cheh; Renate Schnabel; Seiko Makino; Moritz F Sinner; Prince J Kannankeril; Britt M Beckmann; Subbarao Choudry; Brian S Donahue; Jan Heeringa; Siegfried Perz; Kathryn L Lunetta; Martin G Larson; Daniel Levy; Calum A MacRae; Jeremy N Ruskin; Annette Wacker; Albert Schömig; H-Erich Wichmann; Gerhard Steinbeck; Thomas Meitinger; André G Uitterlinden; Jacqueline C M Witteman; Dan M Roden; Emelia J Benjamin; Patrick T Ellinor Journal: Eur Heart J Date: 2009-01-13 Impact factor: 29.983
Authors: Tyler W Barrett; Robert L Abraham; Cathy A Jenkins; Stephan Russ; Alan B Storrow; Dawood Darbar Journal: Am J Cardiol Date: 2012-07-26 Impact factor: 2.778
Authors: Patrick T Ellinor; Kathryn L Lunetta; Nicole L Glazer; Arne Pfeufer; Alvaro Alonso; Mina K Chung; Moritz F Sinner; Paul I W de Bakker; Martina Mueller; Steven A Lubitz; Ervin Fox; Dawood Darbar; Nicholas L Smith; Jonathan D Smith; Renate B Schnabel; Elsayed Z Soliman; Kenneth M Rice; David R Van Wagoner; Britt-M Beckmann; Charlotte van Noord; Ke Wang; Georg B Ehret; Jerome I Rotter; Stanley L Hazen; Gerhard Steinbeck; Albert V Smith; Lenore J Launer; Tamara B Harris; Seiko Makino; Mari Nelis; David J Milan; Siegfried Perz; Tõnu Esko; Anna Köttgen; Susanne Moebus; Christopher Newton-Cheh; Man Li; Stefan Möhlenkamp; Thomas J Wang; W H Linda Kao; Ramachandran S Vasan; Markus M Nöthen; Calum A MacRae; Bruno H Ch Stricker; Albert Hofman; André G Uitterlinden; Daniel Levy; Eric Boerwinkle; Andres Metspalu; Eric J Topol; Aravinda Chakravarti; Vilmundur Gudnason; Bruce M Psaty; Dan M Roden; Thomas Meitinger; H-Erich Wichmann; Jacqueline C M Witteman; John Barnard; Dan E Arking; Emelia J Benjamin; Susan R Heckbert; Stefan Kääb Journal: Nat Genet Date: 2010-02-21 Impact factor: 38.330